Schweinfurthins and Uses Thereof


Neurofibromatosis type 1 (NF1) is a genetic disorder affecting 1 per 3000 individuals on average. Patients develop a variety of developmental benign and malignant pathologies. The most common tumors associated with NF1 are peripheral sheath tumors, including neurofibromas, optical gliomas, and malignant peripheral nerve sheath tumors.

Researchers at the National Cancer Institute (NCI) developed novel analogs of the natural product schweinfurthin that inhibits growth of NF1-associated pathologies. The schweinfurthin analogs show inhibitory activity against mouse and human NF1 cancer cell lines. Glioma, diffuse B cell lymphoma, and leukemia cell lines also show significant sensitivity against the schweinfurthin analogs. 



Potential Commercial Applications: Competitive Advantages:
  • Therapies for tumors associated with NF1, for leukemia, and for diffuse B cell lymphoma
 
  • Specificity of mode of action reduces potential side effects
  • Novel mode of action
  • Inhibitory activity against mouse and human NF1 cancer cell line


Development Stage:
Discovery (Lead Identification)

Inventors:

John Beutler (NCI)  ➽ more inventions...

Karlyne Reilly (NCI)  ➽ more inventions...

David Wiemer (NCI)  ➽ more inventions...

Thomas Turbyville (NCI)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,686,016 issued 2014-04-01
U.S. Pat: 2432466 issued 2010-04-30

Publications:
T.J. Turbyville. et al. PMID: 20442305

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-183-2009
Updated: Mar 20, 2018